Related Experiment Videos
Recent developments in our understanding of primary hyperoxaluria type 2.
1Department of Molecular Pathology, Windeyer Institute of Medical Sciences, University College London, United Kingdom.
Journal of the American Society of Nephrology : JASN
|November 30, 1999
Summary
Human liver hydroxypyruvate reductase (HPR) separates into two forms. Peak B, crucial for physiological hydroxypyruvate and glyoxylate reduction, is key for diagnosing primary hyperoxaluria type 2.
Area of Science:
- Biochemistry
- Enzymology
- Human Physiology
Background:
- Hydroxypyruvate reductase (HPR) is an enzyme involved in metabolic pathways.
- Previous observations noted differing tissue distribution of HPR and glyoxylate reductase activities in humans.
Purpose of the Study:
- To biochemically characterize human liver hydroxypyruvate reductase.
- To investigate the distinct properties of HPR forms and their physiological relevance.
- To support diagnostic criteria for primary hyperoxaluria type 2.
Main Methods:
- Partial purification of hydroxypyruvate reductase from human liver.
- Enzyme separation using chromatofocusing.
- Determination of kinetic parameters (Km) and isoelectric points (pI).
Main Results:
- Human liver HPR resolved into at least two forms (Peak A and Peak B) with different pI values.
- Both forms utilize NADPH, but only Peak B efficiently reduces hydroxypyruvate and glyoxylate.
- Peak B exhibited significantly lower Km for hydroxypyruvate (0.1 mM) compared to Peak A (8 mM).
- Peak A activity overlapped with lactate dehydrogenase, suggesting potential contribution from this enzyme.
Conclusions:
- The distinct kinetic properties of HPR forms explain observed differences in enzyme activity distribution.
- Peak B HPR is likely the physiologically significant form for hydroxypyruvate and glyoxylate metabolism.
- Measuring liver glyoxylate reductase activity is recommended for diagnosing primary hyperoxaluria type 2.